A clinical trial examining the efficacy of two devices to monitor and detect atrial fibrillation (AF), or an irregular heartbeat, in ischemic stroke patients one an implantable device that monitors over 12 months, the other an external device that monitors over a 30-day period found the implantable device is more than three times more effective in detecting AF, and both are a significant improvement over the current standard of care in Alberta, Canada.
E-Mail
IMAGE: An implantable device that monitors for atrial fibrillation over 12 months is more than three times more effective at detecting the condition than standard care, and could help prevent disabling. view more
Credit: Supplied
A clinical trial examining the efficacy of two devices to monitor and detect atrial fibrillation (AF), or an irregular heartbeat, in ischemic stroke patients one an implantable device that monitors over 12 months, the other an external device that monitors over a 30-day period found the implantable device is more than three times more effective in detecting AF, and both are a significant improvement over the current standard of care in Alberta, Canada.
Date Time
Canadian cardiac researchers warn women about risks of heart attack and stroke
Did you know that heart attack and stroke are the number one cause of premature death for women in Canada? Or that Canadian women are five times more likely to die of heart disease than breast cancer? Or that 53 per cent of women who have heart attack symptoms go undiagnosed when they seek medical treatment?
It’s “stunning” facts like these that Canadian cardiac researchers are hoping to get across this Valentine’s Day weekend with the Wear Red Day campaign.
“If you ask Canadian women what they are afraid of, they will say breast cancer,” said Colleen Norris, professor in the Faculty of Nursing and chair of the health systems and policy working group of the Canadian Women’s Heart Health Alliance, which is hosting Wear Red Day.